Struggling The Medicines Company Deals Its Infectious Disease Biz to Melinta for $270M Post author:Sam Post published:November 28, 2017 Post category:BioPharma The Medicines Company is selling its infectious disease business unit to Melinta Therapeutics. Source: BioSpace You Might Also Like Bay Area's Coherus Craters After the FDA Spurns Its Biosimilar for Amgen's Neulasta June 11, 2017 BC Platforms Closes USD $10 Million Series B Financing Led By Debiopharm And To Accelerate Knowledge Platform Development May 8, 2017 The 7 Best Life Science Companies to Work for in 2018 January 10, 2018
BC Platforms Closes USD $10 Million Series B Financing Led By Debiopharm And To Accelerate Knowledge Platform Development May 8, 2017